PapersPMID:37364683
Randomized, Placebo-Controlled, Single-Blind Study of Lutein Supplementation on Carotenoid Status and Cognition in Persons with Multiple Sclerosis.
- findings
- 2
- compound
- 1
- endpoints
- 2
lutein- Study, every finding
- RCT
- Dose studied, every finding
- lutein 20 mg/day for 4 months
What moved
How to read these marks →“There was a significant group by time interaction for MPOD (F = 6.74, P = 0.02), skin carotenoids (F = 17.30, P < 0.01), and serum lutein (F = 24.10, P < 0.01), whereby the treatment group improved in all carotenoid outcomes.”
- Increases macular pigment optical density
very limitedreplicated ×3
- Population
- adults with relapsing-remitting multiple sclerosis; MPOD by heterochromatic flicker photometry
- Increases serum or plasma lutein concentration
very limitedreplicated ×2
- Population
- adults with relapsing-remitting multiple sclerosis; serum lutein by high-performance liquid chromatography
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- adults with relapse-remitting multiple sclerosis (RRMS)
- Participants
- 21
- Comparator
- placebo
- Duration
- 122 days
- Endpoints measured
- 6